共 224 条
[1]
Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
[2]
Miller KD(2022)Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial Lancet 399 1718-1729
[3]
Fuchs HE(2018)Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma Melanoma Res 28 618-628
[4]
Jemal A(2010)Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines J Clin Oncol 28 3042-3047
[5]
Luke JJ(2010)Phase II trial of neoadjuvant temozolomide in resectable melanoma patients Ann Oncol 21 1718-1722
[6]
Rutkowski P(1998)Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases Melanoma Res 8 549-556
[7]
Queirolo P(2019)Neoadjuvant therapy of locally/regionally advanced melanoma Ther Adv Med Oncol 11 1758835919866959-47
[8]
Del Vecchio M(1996)Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response Lab Invest 74 43-3171
[9]
Mackiewicz J(2006)Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 3164-1188
[10]
Chiarion-Sileni V(2014)Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab PLoS One 9 e87705-1531